Total consumer industry M&A deals worth $2.67bn were announced in Asia-Pacific in Q1 2021, led by Essity’s $468.8m acquisition of Asaleo Care, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 82% over the previous quarter and a drop of 69.1% when compared with the last four-quarter average of $8.63bn.
Asia-Pacific held a 12.2% share of the global consumer industry M&A deal value that totalled $21.88bn in Q1 2021. With a 4.17% share and deals worth $912.73m, China was the top country in Asia-Pacific’s M&A deal value across consumer industry.
In terms of deal activity, Asia-Pacific recorded 128 deals during Q1 2021, marking a decrease of 28.5% over the previous quarter and a drop of 3.6% over the last four-quarter average. Japan recorded 30 deals during the quarter.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Asia-Pacific consumer industry M&A deals in Q1 2021: Top deals
The top five consumer industry M&A deals accounted for 52.2% of the overall value during Q1 2021.
The combined value of the top five M&A deals stood at $1.39bn, against the overall value of $2.67bn recorded for the quarter.
The top five consumer industry deals of Q1 2021 tracked by GlobalData were:
1) Essity’s $468.8m acquisition of Asaleo Care
2) The $397m acquisition of Beijing Wukesong Culture & Sports Centre by CIFI Holdings (Group)
3) Kumho Petrochemical’s $182m asset transaction with
4) The $174.18m acquisition of Sakai Ovex by Sakai Textile
5) GL Mountrose Investment Two’s acquisition of Hutchison Whampoa Guangzhou Baiyunshan Chinese MedicineLimited for $169m.